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Background/aim: Silent cerebral infarct (SCI) is an ischemic lesion seen before clinical signs of brain infarct and ischemic changes in
brain tissue. This study aimed to detect SCI with noninvasive methods and to determine related risk factors in patients with sickle cell
anemia (SCA).
Materials and methods: Fifty-four SCA patients who had no history of cerebral infarct and whose neurological examinations were
normal were included in this study. Brain magnetic resonance imaging (MRI) and diffusion MRI were taken and the acquired data was
compared statistically.
Results: SCI was detected in 11.1% (6/54) of the patients. No statistical differences in age, sex, physical examination findings, or
treatments were detected between the 2 groups (with and without SCI). When examined in terms of HbS, the median (min–max) value
in SCI-positive patients was 85.4 (80.5–92.1); the median value was 77.2 (49.0–96.7) in SCI-negative patients. The HbS values of the SCI
group were statistically significantly higher than those of the group without SCI (P = 0.014). Patients with the HbSS or HbSβ0 genotypes
had a significantly higher prevalence of SCI when compared with other sickle cell syndromes (P = 0.038).
Conclusion: SCI is not uncommon among SCA patients in Turkey. The presence of homozygote HbSS/Sβ0 genotype, high MCV, and
HbS are risk factors for SCI.
Key words: Sickle cell anemia, silent cerebral infarct, stroke, magnetic resonance imaging, children

1. Introduction
Sickle cell anemia (SCA) is widely distributed in Africa
and the Mediterranean region [1,2]. Sickle hemoglobin
(Hb) is the most common abnormal Hb in Turkey, with a
frequency of 0.37%–0.60%, and an HbS heterozygosity of
3%–44% in the Çukurova region [3].
Central nervous system (CNS) complications, such
as stroke, are among the most devastating manifestations
of SCA. Silent cerebral infarcts (SCI) are detected by
magnetic resonance imaging procedures but do not
cause abnormalities on neurological examination. These
ischemic lesions seem to be related to the recurrence of
an infarct; either clinical stroke or SCI are associated with
transient ischemic attack (TIA), and also related with mild
mental retardation and future hemorrhagic stroke [4,5].
A plethora of literature is available on SCI in children,
but much less research is available where SCA is concerned,
and rarely includes studies from Turkey. Our study,
conducted in southern Turkey, aimed to detect SCI by

noninvasive imaging methods in patients with SCA before
any possible serious complications, such as CNS events, as
well as to identify the predisposing factors and shed light
on treatment protocols.
2. Materials and methods
Fifty-four SCA patients,including children, adolescents,
and young adults(26 female, 28 male), who had no
previous stroke history or abnormal neurological findings
and were followed-up with by the PediatricHematology
Clinic of Çukurova University, were included in the study.
The patients were aged between 5 and 31 years. These
patients underwent brain magnetic resonance imaging
(MRI) and diffusion MRI for SCI.
A detailed evaluation of the patients’ history
(treatments, crises, erythrocyte transfusions, or apheresis)
was noted. Exclusion criteria included abnormal findings
on neurological examination, a painful or hemolytic crisis
during outpatient clinic control, a history of painful or
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hemolytic crisis within the past 3 months, a history of
infection within the last month, or a blood transfusion
within the last 3 months. Patients without any neurological
findings on physical examination were included in the
study.
Verbal and written informed consent about the purpose
of the examinations was obtained from patients aged >18
years, or from patients’ families (for patients <18 years).
Conventional MRI and diffusion MRI of each patient’s
brain was performed at our hospital, using a 1.5 Tesla MRI
device located in the Department of Radiodiagnostics.
During MRI imaging, the patient was not given any
anesthetic agent. The MRI data were reported by members
of the Radiodiagnostics Academic Staff.
Cerebral silent infarcts were identified as hyperintense
focal lesions in T2 and hypointense focal lesions in T1
that were less than 15mm and greater than 3mm on MRI,
which enables the detection of lesions in regions such as
the basal ganglia that are indistinguishable in computed
tomography (CT) [6–8].
Ethics committee approval (Session No.40, Decision
No. 16, date: 06.03.2015) was obtained from the NonInterventional Clinical Research Ethics Committee of
Çukurova University Faculty of Medicine.
Statistical analysis
The statistical package for the social sciences, which
is known as SPSS (IBM Corp., Armonk, NY, USA) v.
23.0 program was used for statistical analysis of the data.
Categorical measurements were summarized as numbers
and percentages, while continuous measurements were
summarized as median and minimum–maximum.
Fischer’s exact test was used to compare categorical
variables. The Shapiro–Wilk test was used to determine
whether the parameters in the study showed normal
distribution. In comparing continuous measurements
between groups, distributions were checked, and the
Mann–Whitney U test was used for parameters that did
not show normal distribution. In the study, based on the
HbS value according to the MRI results, the sensitivity
and specificity values were calculated according to the

SCI positivity and the area under the ROC curve was
examined. Statistical significance level was established as
0.05 in all tests.
3. Results
Of the 54 SCA patients undergoing follow-up and
treatment at the Pediatric Hematology Department, 6
patients had SCI based on the brain MRI and diffusion
MRI examinations. When the patients are distributed by
age group, 3 of the patients were under the age of 8, 34
were between the ages of 8 and 16, and 17 were older than
16 years. Five (14.7%) of the patients in the 8–16 group
and 1 (5.9%) of the patients over the age of 16 were SCI
(+).When examining the presence of SCI within these
age groups, there was no statistically significant difference
among the age groups (P = 0.756). Distribution of patients
by age group is shown in Table 1.
Patient 1 (S.D.): A 15-year-old female patient was
regularly using folic acid and 18 mg/kg of hydroxyurea.
Her liver was normal in size, but she had developed
otosplenectomy, regularly received blood transfusions,
and had a history of more than 5 painful crises per year.
Without a blood transfusion, her HbS level was 84.7%.
Patient 2 (S.G.): A 19-year-old male patient was
regularly using folic acid, zinc sulfate, deferasirox, and
15 mg/kg hydroxyurea. He had a normal-sized liver prior
surgical splenectomy, a history of painful crises, and acute
chest syndrome. His HbS level was 90.5% (Figures 1 and
2).
Patient 3 (F.D): A 16-year-old male patient was
regularly using folic acid, zinc sulfate, and 8 mg/kg of
hydroxyurea. Hepatomegaly was present. The spleen was
normal in size, and the patient had a history of more than
5 painful crises per year. His HbS level was 83.3%.
Patient 4 (S.B): A 16-year-old female patient was
regularly using folic acid. She had a normal-sized liver,
prior surgical splenectomy, and had only had 1 painful
crisis event. Her HbS level was 80.5%.
Patient 5 (Ç.S.T.): An 8-year-old male patient was
regularly using folic acid, zinc sulfate, and 22 mg/kg of

Table 1. Distribution of patients by age groups.
SCI (+)
(n = 6)

SCI (–)
(n = 48)

Total
(n = 54)

n (%)

n (%)

n (%)

< 8 years

0 (0)

3 (100)

3 (100)

8–16 years

5 (14.7)

29 (85.3)

34 (100)

>16 years

1 (5.9)

16 (94.1)

17 (100)

Age groups

*Fisher’s exact test
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P*

0.756
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Figure 1. Axial FLAIR MR image. Biparietal white matter
hyperintensities with cystic changes at right.

hydroxyurea. Hepatomegaly was present, the spleen was
normal in size, and there was a history of acute chest pain
and painful crises. His HbS level was 92.1%.
Patient 6 (D.T.): A 16-year-old male patient regularly
used folic acid and zinc sulfate. The liver was normal in
size, and autosplenectomy had developed. He had a history
of painful crisis and priapism. His HbS level was 86.1%.
The hemoglobin electrophoresis results of the patients
were examined. In terms of HbS, the median (min–max)
value of SCI-positive patients was 85.4 (80.5–92.1), and
77.2 (49–96.7) in SCI-negative patients. The HbS values
of the SCI group was statistically significantly higher than
that of the group without SCI (P= 0.014). The median
(min–max) HbF values of the groups with and without
SCI were 11.1 (3.5–17.7) and 15.8 (4.7–40.9). When these
2 groups were compared in terms of HbF, no statistically
significant difference was found (P = 0.073) (Table 2).
The median (min–max) MCV values were 94.6
(85.9–115) and 87.0 (57.7–115.5) fL for the patients with
and without SCI, respectively. When the MCV values of
the hemogram were examined, the MCV values of the
patients with SCI were significantly higher than those of
the patients without SCI (P = 0.035) (Table 2).
When the patients were grouped according to Hb
electrophoresis results and Hb mutations, 33 patients had
HbSS or HbSβ0 mutations, and 21 patients had Sβ+ or
other sicklecell syndromes. SCI was present in 6 patients in
the HbSS/Sβ0group, and none of the patients was in the Sβ+
or other sickle cell syndrome group (P = 0.038) (Table 3).

Figure 2. Silent cerebral infarctions in the left frontal and parietal
white matter.

When the drugs used by the patients with sickle cell
anemia were investigated, approximately 80% of the
patients were using hydroxyurea (43 people). However,
in terms of the presence of SCI, no statistical difference
was found between them (P =0.590). Comparison of the
groups in terms of drugs used by patients is summarized
in Table 4.
ROC analysis was performed in terms of the presence
of a cut-off value in determining the statistically significant
HbS measurement in the presence of SCI. As a result of
ROC analysis for HbS, the area under ROC is 0.802; cutoff was detected as 79.6 (P= 0.0001). In other words, the
probability of having SCI was 80% according to the cut-off
value determined. When the patient’s HbS measurement
value was determined to be above 79.6 as a result of the
MRI, SCI was expected with 80.2% probability, 100%
sensitivity, and 60.4% specificity (Table 5, Figure 3).
4. Discussion
One of the most serious complications of SCA is CNS
events. SCI is defined as infarction detected by imaging
methods in cases without neurological symptoms. In
patients with SCA, SCI is seen approximately twice as
often as clinical stroke in the same population [9]. Silent
infarcts are mostly associated with occlusion of small
vessels and are localized in deep white matter or basal
ganglia [10]. Silent infarcts may be a sign of increased risk
of clinical stroke or new and widespread silent infarcts.
Neurological complications may progress to mild mental
retardation due to silent infarcts, transient ischemic
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Table 2. Hemoglobin electrophoresis results.
SCI (+)
(n = 6)

SCI (–)
(n = 48)

Median
(min–max)

Median
(min–max)

HbA

-

15.6 (1.6–42.6)

-

HbS

85.4 (80.5–92.1)

77.2 (49.0–96.7)

0.014

HbF

11.1 (3.5–17.7)

15.8 (4.7–40.9)

0.073

MCV

94.6 (85.9–115.0)

87.0 (57.7–115.5)

0.035

P*

*Mann–Whitney U Test

attacks, severe ischemic attack, or hemorrhagic infarction
[11,12]. Aplastic crisis, acute splenic sequestration, and
pulmonary sequestration are risk factors for these infarcts.
Neurocognitive deficits have been shown in patients with
silent infarction. Treatment approaches to prevent silent
infarcts are uncertain [13].
In a study by Pegelow et al., the rate of SCI was 22% in
SCA patients [14]. In 2010, Bernaudin et al. reported that

SCI was the most common cerebrovascular disease seen in
SCA patients: 28% in childhood before the age of 6 years
[15]. Kwiatkowski et al. found a prevalence of 37% in SCA
patients before the age of 14 years [16].
A recently published article found that 30% of SCA
patients had SCI before the age of 18 years. In the same
study, the annual incidence in childhood was found to be
around 1%, especially in patients with SCA, with regular
follow-up and necessary prophylaxis [17].
SCI can start in infancy. Its frequency increases with
age and can be seen in nearly half of patients during
adolescence. In a study conducted in patients with adult
SCA, the incidence of SCI was reported to be up to 60%
[18]. Based on the current literature, it can be concluded
that SCI is seen in SCA patients in childhood and can reach
serious proportions at later ages. In our study of patients
aged 5 to 31 years, the SCI rate was 11.1%.
This SCI rate is the lowest level to be mentioned in the
literature to date, and is not as high as in the patients who
did not receive the necessary prophylaxis treatment for the
possible follow-up problems. Our study group consisted
of 3 children, 29 adolescents, and 17 young adults. Since
most of the patients were adolescents and the evaluation

Table 3. Distribution of patients according to the results of hemoglobin mutations.

Hemoglobin mutations

SCI (+)
(n = 6)

SCI (–)
(n = 48)

Total
(n = 54)

n (%)

n (%)

n (%)

HbSS and HbSβ0

6 (18.2)

27 (81.8)

33 (100)

Sβ+ or other mutations

0 (0)

21 (100)

21 (100)

P*

0.038

*Fisher’s exact test
Table 4. Comparison of groups in terms of drugs used by patients.
SCI (+)
(n = 6)

SCI (–)
(n = 48)

Total
(n = 54)

n (%)

n (%)

n (%)

Yes

4 (9.3)

39 (90.7)

43 (100)

No

2 (18.2)

9 (81.8)

11 (100)

Yes

1 (33.3)

2 (66.7)

3 (100)

No

5 (9.8)

46 (90.2)

51 (100)

Yes

6 (12)

44 (88)

50 (100)

No

0 (0)

4 (100)

4 (100)

Yes

4 (10.3)

35 (89.7)

39 (100)

No

2 (13.3)

13 (86.7)

15 (100)

Treatment given

Hydroxyurea
Deferasirox
Folic acid
Zinc
*Fisher’s exact test
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P*

0.590
0.303
0.672
0.747
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Table 5. ROC curve analysis results to determine the presence of
SCI according to HbS measurement.

HbS
100

HbS
0.802

95%–Cl%

0.671–0.898

Cut-off

>79.6

Sensitivity (%)

100,0

95%– Cl%

54.1–100.0

Specificity (%)

60.42

95%–Cl%

45.3–74.2

PPV

24.0

NPV

100.0

+LR

2.53

–LR

0.0

P*

0.0001

*ROC curve test

of the patients was based on immediate follow-up results
without a specific follow-up period, we may not have been
able to identify a particular association between the age
group and SCI.
In an SCI transfusion trial with 814 patients aged 5
to 15 years without stroke or seizure history, brain MRI
scans were performed to investigate the correlation of SCI
presence with some clinical and laboratory variables. In
that study, male sex, low Hb level, and high systolic blood
pressure were found to be statistically significant risk
factors for SCI [19]. In our study, 6 patients with SCI were
male, but 4 of these patients were not statistically different
in terms of sex.
Other studies have identified some of the risk factors
for SCI as an increased white blood cell count, presence
of seizures, low Hb values, presence of cerebral artery
stenosis in cerebral MRI angiographs, a low number
of painful crises, and the Senegal haplotype [20]. In a
recent review by the American Hematology Society, SCI
was found in patients with SCA; the HbSS or HbSβ0
mutation-carrying group was found to be twice as likely
to have SCI as other sickle cell syndromes, such as HbSC
and HbSβ+[17]. Similar to the results in the literature, in
our study, patients with HbSS or HbSβ0 mutation had a
significantly higher prevalence of SCI than HbSβ+ or
other sickle-cell syndromes.
SCI is not associated with serious neurological
complaints but is linked with cognitive deficits. In a
study conducted by Kawadler et al. in 2016, IQ tests were
performed in 3 different groups. The IQ of patients with
stroke-experienced SCA was 10 points lower than that of

80
S e ns itiv ity

AUC

60

40

20
AUC = 0.802
P < 0.001

0
0

20

40
60
100-Specificity

80

100

Figure 3. ROC curve to determine SCI presence according to the
HbS measurement.

the SCI population, 6 points lower in the SCA group with
SCI than in the SCA group without SCI, and 7 points lower
in the SCA group than in the normal population [21].
In 2014, Najibah et al. emphasized the importance
of hydroxyurea therapy for primary stroke prevention in
patients with SCA. In that work, a group of patients with
predicted stroke and silent infarction risk through increased
flow velocity in transcranial Doppler ultrasonography was
treated with hydroxyurea for 3 months [22]. At the end of
this period, it was determined that the flow velocities of
the TCD measurements of the patients were significantly
decreased compared with the pretreatment data. There was
a significant increase in the MCV and HbF values in blood
tests before and after treatment. Additionally, as part of the
treatment strategy, a regular blood transfusion for at least 1
year was recommended in the patients with abnormal TCD
measurements [22]. In our patient group, 4 of 6 patients with
SCI were receiving regular hydroxyurea treatment, while 2
of these patients were diagnosed with SCI and hydroxyurea
treatment then followed. Although MCV elevation has been
reported to increase due to hydroxyurea use, in our study,
there was a statistically significant increase in the MCV
values in patients with SCI compared to patients in the group
without SCI. When SCI- and MCV-related publications
were considered, the use of hydroxyurea for prophylaxis
of SCI was found to be associated with significantly higher
MCV in patients than in patients without SCI. Our results
were incompatible with this and other literature data.

1891

NAFİLE SAYMAN et al. / Turk J Med Sci
In our study, the clinical and laboratory investigations
of the patients revealed the presence of homozygous HbSS/
Sβ0 genotype, MCV elevation, and HbS elevation as risk
factors. Although some of the results were consistent with
the literature, others were not. However, our study had
several limitations, including the number of patients, the
broad age distribution of the patients, and the inclusion of
patients with instantaneous values based on the eligibility
criteria, not only during a regular follow-up period.
Our study is one of the few to examine the presence of
SCI in children with SCA in Turkey and different ethnicities.
Most of the previous studies involve patients of African
origin. The presence of SCI is thought to be a predictor of
an early stroke in SCA patients. More extensive studies are
needed in multiple centres in Turkey in order to establish an
exact relationship between the clinical and laboratory data
of children with SCA and the presence of SCI.
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